Skin condition control in patients with chronic skin diseasesusing dermatic products



Cite item

Full Text

Abstract

Chronic skin diseases degrade the patients life quality. Presently, topical steroids are the most efficient drugs for the
treatment of inflammatory skin diseases. However, there is a risk involved in their application: the patient can develop
both systemic and topical adverse effects. As many as 37 patients with atopic dermatitis (including 16 pregnant women)
applied an advanced corticosteroid drug topically for two months (uniderm according to an intermittent regimen: for
two consecutive days with a time window of five days (twice a week) against the background of daily administration
of Emolium, a basic care product. The uniderm administration regimen made it possible to considerably improve the
patients skin condition in most of the cases and improve the life quality in patients with atopic dermatitis.

About the authors

E V Sokolovskiy

K N Monakhov

D K Dombrovskaya

Email: zakomarik@gmail.com

Ye V Sokolovsky

K N Monakhov

D K Dombrovskaya

References

  1. Тополянский В.Д., Струковская М.В. Психосоматические расстройства. М., 1986. 383 с.
  2. Остришко В.В., Иванов О.Л., Новоселов В.С. Диагностика и коррекция пограничных психических расстройств у больных атопическим дерматитом. Вестн. дерматол. и венерол., 1998; 2: 34-37.
  3. von Mutius E. The environmental predictors of allergic disease. J Allergy Clin Immunol 1999; 105: 9-19.
  4. Монахов К.Н. Всероссийский съезд дерматовенерологов, 8-й. М., 2001; 1; 244.
  5. Darsow U., Lubbe J., Taieb A. et al. European Task Forse on Atopic Dermatitis. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005; 19: 3; 286-95.
  6. Современная стратегия терапии атопического дерматита: программа действий педиатра. Согласительный документ Ассоциации детских аллергологов и иммунологов России. М., 2004.
  7. Barnes P.J. New directions in allergic diseases; mechanism-based anti-inflammatory therapies. J Allergy Clin Immunol 2000; 106; 5-16.
  8. Bressinck R., Williams J., Peets E. Comparison of the effect of mometasone furoate ointment 0,1% and hydrocortisone ointment 1% on adrenocortical function in psoriasis patients. Today' s Ther. Trends, 1988; 5: 25-35.
  9. Beverly E. et. al Citokine inhibition by a novel steroid, mometasone furoate. Immunopharmacology Immunotoxicology 1991: 13(3): 251-261.
  10. Veien N.K., Olholm Larsen P., Thestrup-Pedersen K. et al. Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. Brit J Dermatology 1999; 140, 882-86.
  11. Hanifim J., Gopta A.K., Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Brit J Dermatology 2002; 147 3; 528-37.
  12. Wollenberg A., Bieber T. Proactive therapy of atopic dermatitis - an emerging concept. Allergy 2009: 64: 276-278.
  13. Wollenberg A., Schnopp C. Evolution of conventional therapy in atopic dermatitis. Abstract Immunol Allergy Clin North Am. 2010 Aug; 30(3): 351-68.
  14. Соколовский Е.В., Архипов А.В., Монахов К.Н., Цой А.А. и др. Интермиттирующая терапия бетаметазоном атопического дерматита и экземы кистей. Рос. журн. кожн. вен. болезней 2009; 3: 16-21.
  15. Емельянов А.В., Монахов К.Н. Топические кортикостероиды в терапии аллергодерматозов. Значение внегеномного эффекта. Вестн. дерматол. и венерол., 2002; 3: 59-61.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Sokolovskiy E.V., Monakhov K.N., Dombrovskaya D.K., Sokolovsky Y.V., Monakhov K.N., Dombrovskaya D.K.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.